Wall Street consensus, price target range, and equity research thesis
Wall Street currently rates NVO buy with a 12-month price target of $45 (+13.4% upside). The sections below cover the bull case, key risks, and latest earnings context for Novo Nordisk A/S.
Analyst ratings update weekly. Get NVO's next verdict in your inbox.
Free. No account needed. Unsubscribe any time.
Analyst Research Summary
A structured look at the bull case, the risks, and the most recent earnings execution for NVO.
NVO beat estimates last quarter. Below are the key reasons analysts remain constructive and the risks that could change that view.
What keeps the long thesis intact
Wall Street rates NVO buy, giving the bull case institutional backing from 39 analysts.
What can break the setup quickly
No AI-generated risk factors available for NVO yet.
Watch whether new negative commentary on NVO points to these structural risks or is simply reacting to short-term price moves.
Last Quarter
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Stock snapshot, live price chart, key ratios, and company profile.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NVO stock.
NVO has modest upside — analysts rate it "Buy" with a $45 target, implying +13.4% from today's $39.40. This is informational only — verify the data and consider your own risk tolerance before deciding.
Timing depends on your horizon, but the data signals are: consensus rating "Buy" with +13.4% upside to the $45 target.
NVO's consensus 12-month price target is $45, set by 39 Wall Street analysts. The bull case high is $47 and the bear case low is $40. From the current price of $39.40, this implies +13.4% upside.
NVO appears fairly valued — the $45 consensus target is roughly in line with today's $39.40 (+13.4%). It trades at a forward P/E of 1.8x. Targets range from $40 (bear) to $47 (bull), reflecting different assumptions about growth and margins.
NVO reports next quarter. Earnings-week moves are volatile — historically, analyst targets revise upward after a beat and downward after a miss. The current consensus is "Buy" with a $45 target. Consider position sizing rather than going all-in pre-print.
Of 39 analysts covering Novo Nordisk A/S (NVO): 1 Strong Buy, 22 Buy, 13 Hold, 3 Sell, 0 Strong Sell — a "Buy" consensus. The 12-month price target is $45 (range $40–$47). Bullish analysts outnumber bearish by more than 2-to-1.
3 of the 39 analysts covering NVO rate it Sell or Strong Sell. Common concerns include valuation stretch, slowing growth, and sector-specific headwinds — see the Bull vs. Risk cards above for the specific theses on Novo Nordisk A/S.
Financial Data & Software Notice: VCP Scanner is an educational financial research database and stock screening software platform. VCP Scanner does not generate, recommend, or package trade decisions, buy/sell signals, or personalized investment advice. Consensus ratings and price targets reflect aggregated third-party Wall Street analyst research from public SEC filings. See our Terms of Service and Privacy Policy.